ARV-110 Fast tracked for mCRPC

[Longterm101]

Arvinas' ARV-110 Fast Track'd for mCRPC

May 29, 2019 8:49 AMArvinas, Inc. (ARVN)By: Mamta Mayani, SA News Editor

The FDA has granted Fast Track designation to Arvinas' (NASDAQ:ARVN), lead PROTAC protein degrader, ARV-110, for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after treatment with two or more systemic therapies.

The Fast Track designation provides for more frequent interactions with the FDA review team and a rolling review of the NDA.

Preliminary clinical data for the trial will be shared in H2, including safety, tolerability, and PK data

[Fairwind]

You can count the days until a Big Pharma company buys out Arvinas and the clinical trials and their locations will expand greatly....This will give us a much better opportunity to get into a trial....Arvivas IPO was last September and opened at $16/share. Today, in a down market, it rose 5% to $22.23..There's time to still get in on this one ! How much will this drug retail for ? That depends on how much the winning bidder pays for the company...

[Longterm101 in reply to Fairwind]

Another drug that costs $10k a month coming to stores near u soon 😉😉😉

[tallguy2]

Thanks for posting this!